NCT01954992View on ClinicalTrials.gov

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
DRUG

Glufosfamide

Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.

DRUG

Fluorouracil

Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week

Trial Locations (3)

33612

RECRUITING

Moffitt Cancer Center, Tampa

44718

RECRUITING

Gabrail Cancer Center Research, Canton

90603

RECRUITING

Innovative Clinical Research Institute, Whittier

Sponsors
All Listed Sponsors
lead

Eleison Pharmaceuticals LLC.

INDUSTRY